Kilitch Drugs (India) Ltd
KILITCHKilitch Drugs (India) Ltd
KILITCH
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.70 | 2.97 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Kilitch Drugs (India) Limited is engaged in the development and operations of pharmaceutical business. The Company's services range from manufacturing to marketing a host of formulations in solid, liquid and parenteral forms.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 23.77 | 29.79 | 53.89 | 86.49 | 57.45 | 71.19 | 117.14 | 142.52 | 158.85 | 168.71 | ||||||||||
Raw Materials | 8.92 | 10.50 | 26.44 | 48.35 | 29.82 | 36.22 | 65.48 | 74.53 | 79.08 | 140.42 | ||||||||||
| Power & Fuel Cost | 0.97 | 1.06 | 1.11 | 1.42 | 1.62 | 1.57 | 1.92 | 2.15 | 2.43 | |||||||||||
| Employee Cost | 3.47 | 3.38 | 4.30 | 5.28 | 5.69 | 5.24 | 6.18 | 11.73 | 10.01 | |||||||||||
| Selling & Administrative Expenses | 5.17 | 6.98 | 8.19 | 12.56 | 11.50 | 11.17 | 15.34 | 23.53 | 28.24 | |||||||||||
| Operating & Other expenses | 6.76 | 7.27 | 5.28 | 7.60 | 4.28 | 9.01 | 14.81 | 9.93 | 10.35 | |||||||||||
EBITDA | -1.52 | 0.60 | 8.57 | 11.28 | 4.54 | 7.98 | 13.41 | 20.65 | 28.74 | 28.29 | ||||||||||
| Depreciation/Amortization | 10.05 | 9.76 | 2.04 | 2.05 | 2.00 | 1.99 | 2.47 | 3.55 | 3.35 | 3.20 | ||||||||||
| PBIT | -11.57 | -9.16 | 6.53 | 9.23 | 2.54 | 5.99 | 10.94 | 17.10 | 25.39 | 25.09 | ||||||||||
| Interest & Other Items | 0.06 | 0.16 | 0.42 | 0.65 | 0.94 | 0.88 | 1.33 | 5.08 | 6.04 | 4.96 | ||||||||||
| PBT | -11.63 | -9.32 | 6.11 | 8.58 | 1.60 | 5.11 | 9.61 | 12.02 | 19.35 | 20.13 | ||||||||||
| Taxes & Other Items | -0.44 | -0.43 | 0.96 | 4.76 | 0.77 | 1.46 | 2.25 | 1.56 | 4.75 | 3.65 | ||||||||||
| Net Income | -11.19 | -8.89 | 5.15 | 3.82 | 0.83 | 3.65 | 7.36 | 10.46 | 14.60 | 16.48 | ||||||||||
| EPS | -8.46 | -6.72 | 3.82 | 2.63 | 0.54 | 2.36 | 4.74 | 6.71 | 9.22 | 10.25 | ||||||||||
| DPS | 0.00 | 0.00 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.13 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kilitch Drugs (India) Ltd | 35.78 | 2.97 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare KILITCH with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
KILITCH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 20, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Sep 20, 2019
Cash Dividend
Ex DateEx DateSep 18, 2018
Dividend/Share
₹0.50
Ex DateEx Date
Sep 18, 2018
Cash Dividend
Ex DateEx DateSep 24, 2012
Dividend/Share
₹30.00
Ex DateEx Date
Sep 24, 2012
Cash Dividend
Ex DateEx DateAug 18, 2011
Dividend/Share
₹1.00
Ex DateEx Date
Aug 18, 2011
Cash Dividend
Ex DateEx DateOct 14, 2010
Dividend/Share
₹1.00
Ex DateEx Date
Oct 14, 2010
Net profit of Kilitch Drugs (India) rose 81.86% to Rs 8.62 crore in the quarter ended September 2024 as against Rs 4.74 crore during the previous quarter ended September 2023. Sales rose 15.22% to Rs 47.47 crore in the quarter ended September 2024 as against Rs 41.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales47.4741.20 15 OPM %12.8520.92 - PBDT10.957.60 44 PBT10.356.78 53 NP8.624.74 82 Powered by Capital Market - Live
Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Kilitch Drugs (India) announced that the 32th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net profit of Kilitch Drugs (India) declined 60.12% to Rs 1.34 crore in the quarter ended June 2024 as against Rs 3.36 crore during the previous quarter ended June 2023. Sales declined 8.51% to Rs 33.45 crore in the quarter ended June 2024 as against Rs 36.56 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.4536.56 -9 OPM %4.9616.90 - PBDT2.505.24 -52 PBT1.654.53 -64 NP1.343.36 -60 Powered by Capital Market - Live
Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
Krebs Biochemicals & Industries Ltd leads gainers in ‘B’ group
Kilitch Drugs Standalone March 2022 Net Sales at Rs 32.03 crore, up 51.49% Y-o-Y
Kilitch Drugs commences Rs100 crore new facility expansion plan
Kilitch Drugs (India) reports standalone net profit of Rs 2.89 crore in the June 2021 quarter
Kilitch Drugs starts production of Cephalosporin Injectables at Ethiopia Plant; Stock surges 5%
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.93%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.04%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 30.75%, vs industry avg of 15.27%